WITHUS PHARMACEUTICAL Co.,LTD. (KOSDAQ:330350)
6,760.00
-190.00 (-2.73%)
At close: Jun 1, 2026
KOSDAQ:330350 Revenue
In the year 2025, WITHUS PHARMACEUTICAL Co.,LTD. had annual revenue of 106.44B KRW with 3.62% growth. WITHUS PHARMACEUTICAL Co.,LTD. had revenue of 27.18B in the quarter ending December 31, 2025, with 18.99% growth.
Revenue
106.44B
Revenue Growth
+3.62%
P/S Ratio
0.84
Revenue / Employee
899.93M
Employees
121
Market Cap
91.75B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 106.44B | 3.72B | 3.62% |
| Dec 31, 2024 | 102.72B | 22.60B | 28.21% |
| Dec 31, 2023 | 80.12B | 15.44B | 23.87% |
| Dec 31, 2022 | 64.68B | 7.26B | 12.65% |
| Dec 31, 2021 | 57.42B | 4.01B | 7.51% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| H.PIO | 258.19B |
| DongKoo Bio & Pharma | 242.08B |
| Daehan Nupharm | 205.39B |
| Sinsin Pharmaceutical | 118.65B |
| OPTUS Pharmaceutical | 91.62B |
| KOREA PHARMA | 91.42B |
| Sam-A Pharm. | 70.93B |
| Polaris AI Pharma | 63.94B |